At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 260 enrolled
Drug / intervention
0.25% Tanfanercept Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double Masked and Placebo-Controlled Study Evaluating the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution 0.25% Compared to Placebo in Subjects With Dry Eye
In Brief
A Phase 3 clinical trial evaluating 0.25% Tanfanercept Ophthalmic Solution and Placebo for Dry Eye. Completed, enrolled 260 participants across 10 sites.
Detailed Summary
The objective of this study was to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
CollaboratorsDaewoong Pharmaceutical Co. LTD.
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartNov 2021
Primary CompletionMay 2022
TodayJul 2026
First PostedNov 5, 2021
Enrollment StartNov 18, 2021
Primary CompletionMay 6, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.7 years ago
Interventions
0.25% Tanfanercept Ophthalmic Solutiondrug
Tanfanercept ophthalmic solution.
Placebodrug
Placebo vehicle solution.